Peter F Thall

发表

Bayesian treatment comparison using parametric mixture priors computed from elicited histograms

Peter F Thall, Moreno Ursino, Véronique Baudouin, 2019, Statistical methods in medical research.

A review of phase 2–3 clinical trial designs

Peter F Thall, P. Thall, 2008, Lifetime data analysis.

Clinical Trial Design as a Decision Problem.

Peter F Thall, Peter Müller, Yanxun Xu, 2017, Applied Stochastic Models in Business and Industry.

Comparing Bayesian early stopping boundaries for phase II clinical trials.

Peter F Thall, Fangrong Yan, Liyun Jiang, 2020, Pharmaceutical statistics.

Utility‐based designs for randomized comparative trials with categorical outcomes

Ying Yuan, Thomas A Murray, Peter F Thall, 2016, Statistics in medicine.

Seamlessly Expanding a Randomized Phase II Trial to Phase III

Peter F Thall, Donald A Berry, Lurdes Y T Inoue, 2002, Biometrics.

Adaptive Randomization to Improve Utility-Based Dose-Finding with Bivariate Ordinal Outcomes

Peter F Thall, Hoang Q Nguyen, Hoang Q. Nguyen, 2012, Journal of biopharmaceutical statistics.

Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes

Peter F Thall, Thomas M Braun, Hoang Q Nguyen, 2013, Biometrics.

Continuous Bayesian adaptive randomization based on event times with covariates

Peter F Thall, Ying Kuen Cheung, Lurdes Y T Inoue, 2006, Statistics in medicine.

Prior Effective Sample Size in Conditionally Independent Hierarchical Models.

Satoshi Morita, Peter F Thall, Peter Müller, 2012, Bayesian analysis.

Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes

Ying Yuan, Peter F Thall, Suyu Liu, 2014, Journal of the American Statistical Association.

A decision-theoretic phase I-II design for ordinal outcomes in two cycles.

Peter F Thall, Peter Müller, Yuan Ji, 2016, Biostatistics.

A Decision-Theoretic Comparison of Treatments to Resolve Air Leaks After Lung Surgery Based on Nonparametric Modeling.

Peter F Thall, Peter Müller, Yanxun Xu, 2015, Bayesian analysis.

A simulation study of outcome adaptive randomization in multi-arm clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2017, Clinical trials.

Bayesian nonparametric statistics: A new toolkit for discovery in cancer research

Peter F Thall, Michele Guindani, Peter Mueller, 2017, Pharmaceutical statistics.

Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

Peter F Thall, Peter Müller, Yuan Ji, 2015, Journal of the American Statistical Association.

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.

Peter F Thall, P. Thall, 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

An adaptive trial design to optimize dose‐schedule regimes with delayed outcomes

Ying Yuan, Peter F Thall, Ruitao Lin, 2019, Biometrics.

Parametric likelihoods for multiple nonfatal competing risks and death, with application to cancer data

Peter F Thall, Xuemei Wang, 2009 .

Bayesian adaptive model selection for optimizing group sequential clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2008, Statistics in medicine.

A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.

Peter F Thall, Andrew G Chapple, 2018, Biometrics.

Optimization of multi‐stage dynamic treatment regimes utilizing accumulated data

Peter F Thall, Lu Wang, Xuelin Huang, 2015, Statistics in medicine.

Bayesian and frequentist two‐stage treatment strategies based on sequential failure times subject to interval censoring

Peter F Thall, P. Thall, R. Millikan, 2007, Statistics in medicine.

Monitoring event times in early phase clinical trials: some practical issues

Peter F Thall, P. Thall, N. Tannir, 2005, Clinical trials.

Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer

Peter F Thall, Andrea Rotnitzky, Lu Wang, 2012, Journal of the American Statistical Association.

Monitoring late-onset toxicities in phase I trials using predicted risks.

Peter F Thall, Yuan Ji, Yu Shen, 2008, Biostatistics.

Dose‐Finding with Two Agents in Phase I Oncology Trials

Peter F Thall, Peter Mueller, Sang-Joon Lee, 2003, Biometrics.

Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia

Abdus S Wahed, Peter F Thall, P. Thall, 2013, Journal of the Royal Statistical Society. Series C, Applied statistics.

Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics

Satoshi Morita, Peter F Thall, Peter Müller, 2010, Statistics in biosciences.

Phase 1 adaptive dose‐finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high‐risk extremity and trunk soft tissue sarcoma

Peter F Thall, Shouhao Zhou, Janice N Cormier, 2015, Cancer.

Effective sample size for computing prior hyperparameters in Bayesian phase I–II dose-finding

Peter F Thall, Hoang Q Nguyen, Richard C Herrick, 2014, Clinical trials.

Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times

Abdus S Wahed, Peter F Thall, Peter Müller, 2014, Journal of the American Statistical Association.

Bayesian group sequential clinical trial design using total toxicity burden and progression‐free survival

Peter F Thall, Brian P Hobbs, P. Thall, 2016, Journal of the Royal Statistical Society. Series C, Applied statistics.

Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome

Peter F Thall, Michele Guindani, Rebecca Graziani, 2015, Biometrics.

Bayesian non‐parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation

Peter F Thall, Yanxun Xu, William Hua, 2018, Journal of the Royal Statistical Society. Series C, Applied statistics.

Bayesian designs to account for patient heterogeneity in phase II clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2008, Current opinion in oncology.

Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent

Peter F Thall, Thomas M Braun, T. Braun, 2005, Biometrics.

Ethical issues in oncology biostatistics

Peter F Thall, P. Thall, 2002, Statistical methods in medical research.

Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials

Peter F Thall, Ying Kuen Cheung, P. Thall, 2002, Biometrics.

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.

Peter F Thall, Gordon B Mills, Michael T Deavers, 2003, Gynecologic oncology.

Some Geometric Methods for Constructing Decision Criteria Based On Two-Dimensional Parameters.

Peter F Thall, P. Thall, 2008, Journal of statistical planning and inference.

Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer

Thomas A Murray, Peter F Thall, P. Thall, 2017, Journal of the American Statistical Association.

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

Peter F Thall, Paul Mathew, Christopher Logothetis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates

Peter F Thall, Hoang Q Nguyen, Hoang Q. Nguyen, 2008, Biometrics.

Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas.

Peter F Thall, Victor G Prieto, Kelly K Hunt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneously optimizing dose and schedule of a new cytotoxic agent

Peter F Thall, Thomas M Braun, Hoang Q. Nguyen, 2007, Clinical trials.

Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Peter F Thall, Xavier Paoletti, Andrew Kramar, 2010, Biometrics.